XON7 binds tumor antigens and uses its Fc to engage Fcγ receptors (including CD32B) on immune effector cells, triggering ADCC/ADCP and CDC to kill antigen-positive tumor cells; CD32B+ cells are effectors, not targets, and are not directly killed.